Loading...
Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1.
Perin, Paula M Haid, Sibylle Brown, Richard J P Doerrbecker, Juliane Zeilinger, Carsten von Schaewen, Markus Heller, Brigitte Vercauteren, Koen Luxenburger, Eva
Perin, Paula M
Haid, Sibylle
Brown, Richard J P
Doerrbecker, Juliane
Zeilinger, Carsten
von Schaewen, Markus
Heller, Brigitte
Vercauteren, Koen
Luxenburger, Eva
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2016-01
Submitted date
Files
Loading...
original manuscript
Adobe PDF, 3.85 MB
Other Titles
Abstract
To explore mechanisms of hepatitis C viral (HCV) replication we screened a compound library including licensed drugs. Flunarizine, a diphenylmethylpiperazine used to treat migraine, inhibited HCV cell entry in vitro and in vivo in a genotype-dependent fashion. Analysis of mosaic viruses between susceptible and resistant strains revealed that E1 and E2 glycoproteins confer susceptibility to flunarizine. Time of addition experiments and single particle tracking of HCV demonstrated that flunarizine specifically prevents membrane fusion. Related phenothiazines and pimozide also inhibited HCV infection and preferentially targeted HCV genotype 2 viruses. However, phenothiazines and pimozide exhibited improved genotype coverage including the difficult to treat genotype 3. Flunarizine-resistant HCV carried mutations within the alleged fusion peptide and displayed cross-resistance to these compounds, indicating that these drugs have a common mode of action.
Citation
Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1. 2016, 63 (1):49-62 Hepatology
Publisher
Journal
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
1527-3350